文献速递胸部肿瘤放疗放疗物理与技术

质子治疗试验模型化方法的回顾性研究:肺癌随机试验的启示

Perspectives on the model-based approach to proton therapy trials: A retrospective study of a lung cancer randomized trial.
PubMed 文献 · Radiother Oncol · 2020-03-27

该研究回顾性应用基于模型的策略于已完成非小细胞肺癌随机对照试验(NCT00915005),采用三种放射性肺炎NTCP模型和ΔNTCP>5%阈值筛选患者。结果显示仅不到19%(32/165)患者符合模型化试验入组标准,且入组比例随NTCP模型不同(3%、13%、19%)而异,提示质子与光子NTCP差异可能过小,难以支持肺癌模型化试验。

要点

  • 回顾性应用模型化方法于肺癌RCT,仅不到19%患者符合ΔNTCP>5%阈值。
  • 三种NTCP模型筛选比例分别为3%、13%和19%,模型间差异显著。
  • NTCP模型不确定性是模型化试验方法的固有缺陷,影响入组。

核心结论

  • 质子与光子治疗的NTCP差异可能过小,难以支持肺癌基于模型的试验方法。
  • NTCP模型的不确定性是模型化临床试验方法的固有缺陷。

研究设计与样本

  • 回顾性应用基于模型的策略于已完成非小细胞肺癌随机对照试验(NCT00915005)。
  • 采用三种常用放射性肺炎NTCP模型,假设ΔNTCP>5%阈值筛选患者,终点为≥3级放射性肺炎首次发生。

主要发现

  • 已完成试验中不到19%(32/165)患者符合模型化试验入组标准,其余患者均接受光子治疗。
  • 入组患者数量取决于NTCP模型类型,三种模型分别入组3%、13%和19%的患者。
  • 无法对模型化方法随机化患者的放射性肺炎发生情况做出统计学结论。

关键数值与推荐

  • 模型化方法筛选阈值:预期ΔNTCP>5%。
  • 终点:≥3级放射性肺炎首次发生,与原试验一致。

临床怎么用

  • 对于肺癌等特定治疗部位,基于NTCP差异的模型化试验方法可能因差异过小而受限。
  • 应用模型化方法需考虑NTCP模型不确定性对入组的影响。

局限性

  • NTCP模型预测结果存在不确定性,是模型化方法的固有缺陷。
  • 无法对模型化方法随机化患者的放射性肺炎发生情况做出统计学结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The goal of this study was to assess whether a model-based approach applied retrospectively to a completed randomized controlled trial (RCT) would have significantly altered the selection of patients of the original trial, using the same selection criteria and endpoint for testing the potential clinical benefit of protons compared to photons. METHODS AND MATERIALS: A model-based approach, based on three widely used normal tissue complication probability (NTCP) models for radiation pneumonitis (RP), was applied retrospectively to a completed non-small cell lung cancer RCT (NCT00915005). It was assumed that patients were selected by the model-based approach if their expected ΔNTCP value was above a threshold of 5%. The endpoint chosen matched that of the original trial, the first occurrence of severe (grade ≥3) RP. RESULTS: Our analysis demonstrates that NTCP differences between proton and photon therapy treatments may be too small to support a model-based trial approach for lung cancer using RP as the normal tissue endpoint. The analyzed lung trial showed that less than 19% (32/165) of patients enrolled in the completed trial would have been enrolled in a model-based trial, prescribing photon therapy to all other patients. The number of patients enrolled was also found to be dependent on the type of NTCP model used for evaluating RP, with the three models enrolling 3%, 13% or 19% of patients. This result does show limitations in NTCP models which would affect the success of a model-based trial approach. No conclusion regarding the development of RP in patients randomized by the model-based approach could statistically be made. CONCLUSIONS: Uncertainties in the outcome models to predict NTCP are the inherent drawback of a model-based approach to clinical trials. The impact of these uncertainties on enrollment in model-based trials depends on the predicted difference between the two treatment arms and on the set threshold for patient stratification. Our analysis demonstrates that NTCP differences between proton and photon therapy treatments may be too small to support a model-based trial approach for specific treatment sites, such as lung cancer, depending on the chosen normal tissue endpoint.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. McNamara AL, Hall DC, Shusharina N, et al. Perspectives on the model-based approach to proton therapy trials: A retrospective study of a lung cancer randomized trial. Radiother Oncol. 2020. PMID: 32224318. doi:10.1016/j.radonc.2020.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。